Would you offer a RET inhibitor for a RET-mutated medullary thyroid carcinoma after R1 resection in a patient with elevated calcitonin?

RET inhibitors have not yet been studied in the adjuvant setting in MTC (or in other RET-driven cancers for that matter). Thus, it is not considered SOC to start a RET specific inhibitor in the adjuvant setting following surgery for MTC, even when calcitonin and/or CEA are elevated. In the post-oper...